{"id":"W4415734869","doi":"10.1182/bloodadvances.2025017745","title":"Decitabine-cedazuridine in patients with MDS and <i>TP53</i> mutations","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology; University of Texas MD Anderson Cancer Center; Genentech; Sierra Oncology; Daiichi Sankyo Europe; Gilead Sciences; Servier; Celldex Therapeutics; Daiichi-Sankyo; Pfizer; Incyte; CTI Biopharma; Agios Pharmaceuticals; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Celgene; BioCryst; Syndax Pharmaceuticals; Acceleron; Astex Pharmaceuticals; Ipsen; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Karyopharm Therapeutics; Ipsen Biopharmaceuticals; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma; Amgen","keywords":"Propensity score matching; Parenteral nutrition; Hypomethylating agent; Myelodysplastic syndromes; Cohort; Overall survival; Retrospective cohort study","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001961293,0.0002287892,0.0005192014,0.0002420899,0.0002094575,0.0002344421,0.0001740617,0.0003194889,0.001317477],"category_scores_gemma":[0.0007782225,0.00009433623,0.0002250429,0.0002535068,0.0001184922,0.0002167593,0.0001534175,0.0004462877,0.0001504586],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005179326,"about_ca_system_score_gemma":0.0003412243,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001206807,"about_ca_topic_score_gemma":0.004165016,"domain_scores_codex":[0.999885,0.00003544712,0.00001426788,0.00002078737,0.00001836033,0.00002609534],"domain_scores_gemma":[0.9998556,0.00004929763,0.00002948276,0.000008553518,0.00001107664,0.0000459824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1149946,0.001086795,0.4808137,0.0006977597,0.001162801,0.007312696,0.0003468313,0.002052988,0.04764732,0.0006948425,0.005154642,0.338035],"study_design_scores_gemma":[0.006387431,0.01848449,0.9195551,0.0002361301,0.001390677,0.01333627,0.0004858955,0.002524562,0.01327003,0.00098846,0.0232806,0.00006043899],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884728,0.006695705,0.0001156346,0.000681508,0.00006757622,0.00003245043,0.0003176171,0.0000214677,0.003595229],"genre_scores_gemma":[0.9983249,0.0007277416,0.0001217829,0.0001449411,0.00002678951,0.00001102117,0.0002390726,0.000002030105,0.0004016996],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001317477,"threshold_uncertainty_score":0.004407406,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.003920591795927492,"score_gpt":0.262517802524773,"score_spread":0.2585972107288455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}